Dermatology

The AI-based point-of-care device outperformed clinician standard of care for sensitivity (90% vs 40%) and had a negative predictive value of 98.9%

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.

In a study of patients with CHE, 75.5% of participants totally or almost agreed that topical corticosteroids cause damage to skin.

Your daily dose of the clinical news you may have missed.

The steroid-free cream was developed for long-term use and has been proven safe in an open-label extension study following successful phase 3 trials.

The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.

Your daily dose of the clinical news you may have missed.

Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.

AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.

AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

Statin-eligible patients in minority groups significantly undertreated; metabolically healthy obesity on the rise; menstruation irregularities suggest later CVD risk; and 2 more studies of note.

Survey: More than half of Gen Z respondents wish they had taken sun protection more seriously when they were younger. Find out where the information gaps are.

Another new COVID-19 vaccine, the first and only once-daily amphetamine transdermal patch approved for the treatment of ADHD, and 5 more.

A rash presumed to be a possible fungal or bacterial infection on the legs and feet of a 62-year-old man has failed to improve after 10 days of treatment. What's your Dx?

The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.

Dupilumab therapy for 4 weeks in adults with severe atopic dermatitis resulted in significant improvements in clinical outcomes with no adverse events reported.

Two first-in-class migraine drugs, the first generic version of NuvaRing®, and 7 more fourth quarter FDA-approved drugs for primary care.

Summer brings sunburn, chemical exposure, allergies, and heat-related ills. Catch up on recent research on some of the unpleasant syndromes of summer.

Patient claims pruritic full-body rash is from a course of vancomycin. Is he correct? Could it be something else?